Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : The companies will jointly conduct research activities to identify and optimize proprietary LENS Integrated Intelligence Technology in silico generated antibodies, targeting an undisclosed target in the TME, as potential therapeutic development candidate...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
March 30, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : OmniAb
Deal Size : Undisclosed
Deal Type : Licensing Agreement
IPA’s Subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs
Details : Under the terms of the agreement, Talem will oversee the development and optimization of the antibodies for each program. OmniAb and Talem will share downstream economics upon potential out-licensing or commercialization of the OmniChicken-derived antibo...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 10, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : OmniAb
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the research collaboration, scientists from both companies will work together and contribute their respective resources to discover and develop novel antibodies leveraging the IPA group’s antibody discovery technologies.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
July 10, 2021